Related Experiment Videos
cAMP-mediated signal transduction and sarcoplasmic reticulum function in heart failure
1Salt Lake City VA Medical Center, Utah, USA. matthew.movsesian@hsc.utah.edu
Abstract:
There is evidence that the effects of beta-adrenergic receptor agonists on myocardial contractility result principally from the phosphorylation of phospholamban by cAMP-dependent protein kinase and the consequent deinhibition of SERCA2 activity and stimulation of sarcoplasmic reticulum Ca2+ transport. An impairment in beta-adrenergic receptor-stimulated cAMP generation, attributable to down-regulation of beta 1-adrenergic receptors and increased activity of G alpha i and G protein-coupled receptor kinase, has long been recognized in failing human myocardium. This impairment is associated with a compartment-specific decrease in sarcoplasmic reticulum cAMP content that may selectively reduce phospholamban phosphorylation. Published and preliminary results indicate that two plausible explanations for this compartment-specific decrease--a reduction in sarcoplasmic reticulum-associated cAMP-dependent protein kinase or an increase in sarcoplasmic reticulum-associated cAMP phosphodiesterase--are unlikely. Instead, there is reason to believe that the selective reduction in beta 1-adrenergic receptor density in failing myocardium is causally related to this compartment-specific decrease in cAMP content through an as-yet-undetermined mechanism. The fact that the modulation of SERCA2 activity by phospholamban is preserved in failing human myocardium offers an opportunity for improvement in the therapy of heart failure.
Insights
In heart failure, reduced beta-adrenergic receptor signaling impairs myocardial contractility. However, preserved phospholamban modulation of SERCA2 offers potential therapeutic strategies for heart failure.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- Beta-adrenergic receptor agonists enhance myocardial contractility via phospholamban phosphorylation and SERCA2 activity.
- Heart failure is characterized by impaired beta-adrenergic receptor signaling and reduced cAMP generation.
- This impairment is linked to decreased beta 1-adrenergic receptor density and altered G protein activity.
Purpose of the Study:
- To investigate the mechanisms underlying compartment-specific decreases in cAMP content in failing human myocardium.
- To explore the relationship between reduced beta 1-adrenergic receptor density and cAMP signaling defects.
- To assess the therapeutic potential of preserved phospholamban-SERCA2 interactions in heart failure.
Main Methods:
- Analysis of beta-adrenergic receptor signaling pathways in human failing myocardium.
- Measurement of cAMP levels and protein phosphorylation in specific cellular compartments.
- Assessment of sarcoplasmic reticulum Ca2+ transport and phospholamban modulation.
Main Results:
- A compartment-specific decrease in cAMP content was observed in failing myocardium, potentially reducing phospholamban phosphorylation.
- Reduced beta 1-adrenergic receptor density in failing hearts is implicated in this cAMP signaling deficit.
- Mechanisms involving cAMP-dependent protein kinase or phosphodiesterase activity were largely excluded.
Conclusions:
- The selective reduction in beta 1-adrenergic receptors is a key factor in impaired cAMP signaling in heart failure.
- Despite signaling deficits, the functional modulation of SERCA2 by phospholamban remains intact.
- This preserved interaction presents a promising target for novel heart failure therapies.